TNXP - Tonix Pharmaceuticals Holding Corp.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.8500
-0.0300 (-1.04%)
As of 11:59AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.1700
Open3.1400
Bid2.7800 x 1300
Ask2.7900 x 1000
Day's Range2.8100 - 2.8600
52 Week Range0.3600 - 9.6000
Volume533,349
Avg. Volume1,329,111
Market Cap6.815M
Beta (3Y Monthly)1.06
PE Ratio (TTM)N/A
EPS (TTM)-28.5240
Earnings DateMar 13, 2019 - Mar 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 hours ago

    Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix, or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, today announced financial results for the fourth quarter and full year ended December 31, 2018, and an overview of recent operational highlights. “Looking forward into 2019, we are excited about the recent initiation of our new Phase 3 study of Tonmya for PTSD.

  • GlobeNewswire6 days ago

    Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences

    Investors interested in arranging a meeting with the Company’s management during either conference should contact the respective conference coordinator. Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures.

  • ACCESSWIRE7 days ago

    Four Healthcare Stocks Making Moves on Monday

    CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The future of the healthcare stock market, and the medical sector in its entirety, is largely dependent on whether medical experts and healthcare professionals are aptly prepared to meet the growing demands of patients. As companies in the healthcare sector work to develop innovative technologies for their patients, these efforts may create potential opportunities for investors looking to the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Axovant Sciences Ltd (AXGT), Tonix Pharmaceuticals Holding Corp (TNXP), and Cellect Biotechnology Ltd (APOP) are 4 healthcare companies looking to kick off a strong week of trading.

  • GlobeNewswire7 days ago

    Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced today that the first participant was enrolled in the RECOVERY study, a new Phase 3 study of Tonmya* (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of posttraumatic stress disorder (PTSD). “Tonix is committed to improving the lives of the millions who suffer from PTSD, especially military-related PTSD, and enrolling the first participant in the RECOVERY study is an important step towards achieving this goal,” said Seth Lederman, M.D., Tonix's President and Chief Executive Officer.

  • ACCESSWIRE10 days ago

    Four Healthcare Stocks Surpassing Investor Expectations

    CORAL GABLES, FL / ACCESSWIRE / March 8, 2019 / When it comes to discussing healthcare stock market, it goes without saying that the success of the market is directly connected to if companies in the healthcare industry are doing their part to take care of consumers. It is the responsibility of healthcare companies to work to develop innovative treatments and care options for consumers, especially at a time where new diseases are discovered on a frequent basis. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Tonix Pharmaceuticals Holding Corp (TNXP), Steller Biotechnologies Inc (SBOT), NantHealth Inc (NH) are 4 healthcare companies stepping up their game on Friday.

  • GlobeNewswire11 days ago

    Tonix Pharmaceuticals Announces New European Use Patent for TNX-601

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, today announced that the European Patent Office (EPO) issued European Patent No. 3246031 to the Company on February 27, 2019. The patent, “Method for Treating Neurodegenerative Dysfunction,” claims the use of TNX-601, or tianeptine oxalate and other salts, for treating neurocognitive dysfunction associated with corticosteroid treatment.

  • GlobeNewswire17 days ago

    Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, today announced program updates related to the development of Tonmya* (cyclobenzaprine HCl sublingual tablets) which is in Phase 3 development for the treatment of posttraumatic stress disorder (PTSD). The U.S. Food and Drug Administration (FDA) notified the Company that the Breakthrough Therapy designation (BTD) granted for Tonmya for PTSD in December 2016 has been rescinded because interim analysis data on Tonmya from the HONOR study do not support the continuation of the BTD. The BTD granted to Tonmya was based on retrospective analysis of the effect of Tonmya 5.6 mg in the Phase 2 AtEase study in military-related PTSD, that shows a substantial improvement over existing therapies in military-related PTSD.

  • GlobeNewswire17 days ago

    Tonix Pharmaceuticals Announces Share Repurchase Program

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) today announced that its Board of Directors has approved a share repurchase program pursuant to which the Company may repurchase up to $2 million in value of its outstanding common stock, par value, $0.001 per share, from time to time on the open market and in privately negotiated transactions subject to market conditions, share price and other factors (the “Share Repurchase Program”). The Company intends to fund the Share Repurchase Program with available cash. The timing and amount of any shares repurchased will be determined based on the Company’s evaluation of market conditions and other factors and the program may be discontinued or suspended at any time.

  • GlobeNewswire27 days ago

    Tonix Pharmaceuticals Announces New Board Member, James Treco

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) today announced the appointment of James Treco to its Board of Directors, effective immediately. Mr. Treco assumes the seat held by Charles Mather, who has stepped down from the position of company director that he has held since 2011. Seth Lederman, M.D., President and Chief Executive Officer of Tonix commented, “We are pleased to welcome Mr. Treco to the Tonix Board.

  • How Many Insiders Bought Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Shares?
    Simply Wall St.last month

    How Many Insiders Bought Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companies Read More...

  • GlobeNewswirelast month

    Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at the 21st Annual BIO CEO & Investor Conference on February 11, 2019. A live webcast and subsequent archived recording of the Company presentations will be available under the IR Events tab of the Investor Relations section of the Tonix Pharmaceuticals website at www.tonixpharma.com.

  • Zacks Small Cap Research2 months ago

    TNXP: Additional Details Revealed for Phase 3 Trial of TNX-102 SL in PTSD Starting in 1Q19…

    2) Inclusion will be limited to individuals with PTSD who experienced their trauma within the past nine years, while the HONOR trial included individuals who experienced a trauma from 2001 or later. 3) The study will include both civilian and military PTSD patients, while the HONOR trial had limited inclusion to only those with military-related PTSD.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at two investor conferences in January 2019.

  • GlobeNewswire3 months ago

    Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced that it has regained compliance with the minimum bid price requirement for continued listing on the NASDAQ Global Market. On November 28, 2018, Tonix effected a 1-for-10 reverse stock split of its outstanding common stock intended to increase the per share trading price of Tonix’s common stock to satisfy the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Global Market, as set forth in NASDAQ Listing Rule 5450(a)(1) (the “Bid Price Rule”).

  • GlobeNewswire3 months ago

    Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced today the closing of its previously announced underwritten public offering with total gross proceeds of approximately $15,000,000 before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The Company expects to use the net proceeds from this offering to help fund the new Phase 3 RECOVERY study using a modified trial design for its lead product candidate, Tonmya®*, and for working capital and other general corporate purposes. The securities sold by the Company consist of (i) 861,710 Class A Units at a public offering price of $3.50 per unit, with each unit consisting of one share of Common Stock and a Warrant to purchase one share of Common Stock, and (ii) 11,984 Class B Units at a public offering price of $1,000 per unit, with each unit consisting of one share of Series A Convertible Preferred Stock, with a conversion price of $3.50 per share, and Warrants to purchase 285.7143 shares of Common Stock.

  • Nano Cap News: Why Tonix Pharmaceuticals (TNXP) Stock Is Moving Today
    InvestorPlace3 months ago

    Nano Cap News: Why Tonix Pharmaceuticals (TNXP) Stock Is Moving Today

    Tonix Pharmaceuticals (NASDAQ:TNXP) says that it is holding a new public offering that has a total value of $15 billion. The company notes that it plans to use funds from this public offering to fuel a new Phase 3 study for TNX-102 SL, which is its lead product candidate. According to Tonix Pharmaceuticals, it will be selling Class A and Class B shares of its stock during the public offering.

  • ACCESSWIRE3 months ago

    Tonix Pharmaceuticals Prepares for Phase III Trial for Tonmya, Analysts Review and Target

    NEW YORK, NY / ACCESSWIRE / December 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Tonix Pharmaceuticals Holding Corp. (TNXP), a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix is developing Tonmya, which has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed trade name for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of PTSD. New composition of matter patent was issued in November which expands the Company's intellectual property protection for Tonmya, or TNX-102 SL, in the U.S. The patent is part of an expanding portfolio of patents and patent applications and other intellectual property addressing the formulation, manufacturing, and uses of Tonmya, or TNX-102 SL, for a variety of indications including posttraumatic stress disorder, agitation in Alzheimer's disease and fibromyalgia.

  • GlobeNewswire4 months ago

    Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock. The reverse stock split was previously approved by the Board of Directors of Tonix in accordance with Nevada law, under which no stockholder approval is required, and is intended to increase the per share trading price of Tonix’s common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Global Market (Rule 5450(a)(1)). Tonix’s common stock will continue to trade on the NASDAQ Global Market under the symbol “TNXP” and under a new CUSIP number, 890260508.

  • GlobeNewswire4 months ago

    Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Zacks Small Cap Research4 months ago

    TNXP: Ready to Initiate Phase 3 Trial of TNX-102 SL in PTSD in 1Q19…

    On October 31, 2018, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the company will be initiating a new Phase 3 trial for TNX-102 SL in posttraumatic stress disorder (PTSD) in the first quarter of 2019. 1) The primary endpoint will be the change from baseline in CAPS-5 score at 4 weeks. 2) Inclusion will be limited to individuals with PTSD who experienced their trauma within the past nine years, while the HONOR study included individuals who experienced a trauma from 2001 or later.

  • Associated Press4 months ago

    Tonix: 3Q Earnings Snapshot

    The New York-based company said it had a loss of 57 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...

  • GlobeNewswire4 months ago

    Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights

    New Phase 3 Trial of Tonmya® for the Treatment of PTSD to Commence First Quarter 2019 NEW YORK, Nov. 09, 2018 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix or.

  • GlobeNewswire4 months ago

    Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya®

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,117,936 to the Company on November 6, 2018. This patent, “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride,” includes 34 claims directed to pharmaceutical compositions of eutectics of cyclobenzaprine hydrochloride and mannitol and methods of making those compositions.  This patent is expected to provide Tonix with U.S. market exclusivity until 2034. The patent is part of an expanding portfolio of patents and patent applications and other intellectual property addressing the formulation, manufacturing, and uses of Tonmya*, or TNX-102 SL, for a variety of indications including posttraumatic stress disorder, agitation in Alzheimer’s disease, and fibromyalgia.